This article is more than 5 years old. Information may no longer be current.

VIDEO: Tumor-infiltrating lymphocytes may predict response to immunotherapy in breast cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Determining which tumor-infiltrating lymphocytes may predict response to immunotherapy among patients with breast cancer, and identifying biomarkers that indicate cell activation, are areas of research that are “hypothesis-generating, but not quite ready for clinical use,” according to Douglas Yee, MD, of the Masonic Cancer Center at the University of Minnesota.

Yee, who is also a HemOnc Today Editorial Board member, reviews research in this area and related challenges. He also points to a need for standardized assays to identify these biomarkers that can be used throughout different hospitals and laboratories.

“Just as we took several years to standardize the testing for HER-2, I think it will take a little bit of time, if not more, to come up with a good immuno-predictive biomarker for the therapies that are moving forward,” Yee said.